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We thank Dr Lin for the letter to our article.
In our article,1 we gave the first systematic overview
of vascular access calcification and described risk
factors for the development of vascular access calcification
such as male gender, diabetes mellitus, and dialysis
vintage. Moreover, we found that the presence of vascular
access calcification is related to an increased mortality risk,
even after adjustment for these and other important
confounders. Therefore, the detection of vascular access
calcification represents a cost-effective and easy-to-
perform method to identify patients at increased
mortality risk.
As pointed out by Dr Lin, not only vascular access,
calcification, but also high-sensitive C-reactive protein,
carotid intima media thickness, and iliacal/femoral
calcification were related to increased mortality in our
study (Table 4 of original article1), and therefore could be
potential confounding factors on the predictive value of
vascular access calcification on mortality. In addition, we
performed a stepwise Cox regression analysis with the
above-mentioned potential confounders plus age (Table 1).
In this model we found that, even after adjustment of these
confounders, the presence of vascular access calcification
was associated with an approximately twofold mortality
risk (ranging from 1.77 to 2.60).
Taken together, the presence of vascular access calcifica-
tion is an important predictor of mortality in dialysis
patients.
1. Schlieper G, Kru¨ger T, Djuric Z et al. Vascular access calcification predicts
mortality in hemodialysis patients. Kidney Int 2008; 74: 1582–1587.
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To the Editor: Reich et al.1 investigated the angiotensin-
converting enzyme 2 (ACE2) gene and protein expression in
patients with diabetic nephropathy. The authors seem to
interchangeably use kidneys in patients with diabetes and
diabetic patients with kidney disease (i.e., diabetic nephro-
pathy), which are two different diagnoses. For example, ‘The
strengths of the current study are that we compared ACE2
and ACE expression in the kidney of subjects with type 2 DM
with the kidneys of healthy control subjectsy’1 seems to
conflict with the study by Tikellis et al.,2 which reported
ACE2 expression in rats with streptozocin-induced diabetes
after 24 weeks. The different glomerular expression of ACE2
in these two studies may not be a conflicting report but a
report of ACE2 expression in two separate cohorts. This
raises two questions: (1) Is there a difference in ACE2 gene
and protein expression between patients with diabetes
without nephropathy and diabetic patients with nephro-
pathy? and (2) is there a specific pattern of expression that
may predict future development of nephropathy in diabetic
patients without nephropathy?
Also, Parving et al.3 reported the antiproteinuric effect of
the renin inhibitor, aliskiren (in combination with Losartan)
in patients with diabetic nephropathy. As ACE2 activity is
dependent on production of angiotensin peptides from
angiotensin I and II, and angiotensin I is produced by the
action of renin on angiotensinogen, the use of renin
inhibitors will decrease production of angiotensin I as well
as angiotensin peptides 1–7 and 1–9. It would be interesting
to know what the long-term effect of rennin inhibitors will
be. The use of renin inhibitors may reduce or eliminate the
beneficial effect of the ACE2 pathway.
1. Reich HN, Oudit GY, Penninger JM et al. Decreased glomerular and
tubular expression of ACE2 in patients with type 2 diabetes and kidney
disease. Kidney Int 2008; 74: 1610–1616.
2. Tikellis C, Johnston CI, Forbes JM et al. Characterization of renal
angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension
2003; 41: 392–397.
Table 1 | Effect of vascular access calcification on total
mortality determined by stepwise Cox regression analysis
Model HR 95% CI P-value
Step 1 Vascular access calcification 2.14 1.11–4.12 0.023
Step 2 Step 1 + gender 2.29 1.15–4.55 0.018
Step 3 Step 2 + diabetes mellitus 2.24 1.12–4.49 0.023
Step 4 Step 3 + dialysis vintage 2.60 1.25–5.40 0.010
Step 4 + iliacal/femoral calcification 2.39 1.14–4.99 0.021
Step 4 + CRP 2.27 1.08–4.80 0.032
Step 4 + IMT 1.99 0.87–4.53 0.103
Step 5 Step 4 + age 2.53 1.24–5.15 0.010
Step 6 Step 5 + iliacal/femoral calcification 2.38 1.16–4.90 0.018
Step 7 Step 6 + CRP 2.02 0.94–4.34 0.070
Step 7 + IMT 1.77 0.77–4.05 0.180
CRP, high sensitive C-reactive protein (mg/l); 95% CI, 95% confidence interval; HR,
hazard ratio; IMT, carotid intima-media thickness (mm).
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